EGFR and hepatocellular carcinoma: In a national cohort study of 1616 HCC patients who underwent ctDNA analysis, the incidence of EGFR amplification was 6.5%, which may be related to the drug resistance to lenvatinib.35 Therefore, the detection of EGFR alterations in ctDNA can potentially be used to assist in screening subset patients who may benefit from treatment of lenvatinib plus gefitinib.